We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.5%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.46B
AUM Growth
-$315M
Cap. Flow
+$85.5M
Cap. Flow %
1.32%
Top 10 Hldgs %
48.84%
Holding
76
New
7
Increased
23
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$362M
2
DYN icon
Dyne Therapeutics
DYN
+$95.8M
3
INSM icon
Insmed
INSM
+$68.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
GKOS icon
Glaukos
GKOS
+$34.8M

Top Sells

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$163M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$149M
3
SYK icon
Stryker
SYK
+$115M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$94M
5
TMO icon
Thermo Fisher Scientific
TMO
+$64.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
51
DELISTED
Tourmaline Bio
TRML
$9.54M 0.15%
741,656
– –
VRDN icon
52
Viridian Therapeutics
VRDN
$2.57B
$7.88M 0.12%
605,816
– –
PCSC
53
DELISTED
Perceptive Capital Solutions
PCSC
$7.47M 0.12%
+742,500
New +$7.48M
ORKA
54
Oruka Therapeutics
ORKA
$5.92B
$5.36M 0.08%
+116,667
New +$4.65M
IMUX icon
55
Immunic
IMUX
$211M
$5.07M 0.08%
456,772
– –
GPCR icon
56
Structure Therapeutics
GPCR
$3.71B
$4.91M 0.08%
+125,000
New +$5.13M
SLRN
57
DELISTED
ACELYRIN
SLRN
$4.31M 0.07%
978,310
– –
MIST icon
58
Milestone Pharmaceuticals
MIST
$149M
$4.3M 0.07%
3,256,102
– –
RGNX icon
59
Regenxbio
RGNX
$692M
$4.09M 0.06%
350,000
– –
ALUR
60
DELISTED
Allurion Technologies
ALUR
$3.69M 0.06%
147,902
+9,594
+7% +$442K
XGN icon
61
Exagen
XGN
$163M
$2.75M 0.04%
1,511,866
+7,264
+0.5% +$12.3K
SABS icon
62
SAB Biotherapeutics
SABS
$300M
$2.38M 0.04%
766,946
-150,881
-16% -$553K
CUTR
63
DELISTED
Cutera, Inc.
CUTR
$2.01M 0.03%
1,331,776
– –
SGMT icon
64
Sagimet Biosciences
SGMT
$527M
$1.71M 0.03%
500,000
-499,147
-50% -$2.29M
ARYD
65
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.47M 0.02%
127,970
– –
CTMX icon
66
CytomX Therapeutics
CTMX
$740M
$1.46M 0.02%
+1,200,002
New +$2.39M
ACET icon
67
Adicet Bio
ACET
$76.4M
$1.27M 0.02%
65,856
-192,558
-75% -$5.16M
RCKTW icon
68
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$21.2K ﹤0.01%
350,000
– –
AVDL
69
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-8,798,558
Closed -$149M
EXAS
70
DELISTED
Exact Sciences
EXAS
– –
-95,000
Closed -$6.56M
JANX icon
71
Janux Therapeutics
JANX
$976M
– –
-1,000,000
Closed -$37.6M
LRMR icon
72
Larimar Therapeutics
LRMR
$428M
– –
-650,000
Closed -$4.93M
SYK icon
73
Stryker
SYK
$130B
– –
-321,000
Closed -$115M
TMO icon
74
Thermo Fisher Scientific
TMO
$216B
– –
-110,500
Closed -$64.2M
XAIR icon
75
Beyond Air
XAIR
$4.01M
– –
-3,012
Closed -$2.1M
1 2
3
4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q2 2024 Portfolio in Review

As of Q2 2024, RTW Investments held 76 positions worth $6.46B, down 4.7% from $6.77B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

RTW Investments's Q2 2024 filing shows 7 new, 23 increased, 12 reduced and 8 closed positions. Its largest new stake was Cullinan Oncology: 1,052,630 shares worth $18.4M. The largest sale was Ultragenyx Pharmaceutical, an estimated $163M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q2 2024 buy was Cullinan Oncology: 1,052,630 shares worth $18.4M.
  • RTW Investments added most to Madrigal Pharmaceuticals in Q2 2024, an estimated $362M increase.
  • RTW Investments's biggest Q2 2024 reduction was Ultragenyx Pharmaceutical, cutting an estimated $163M.
  • RTW Investments fully exited Avadel Pharmaceuticals in Q2 2024, selling an estimated $149M.
  • RTW Investments's ten largest holdings make up 49% of its $6.46B portfolio in Q2 2024.
  • RTW Investments opened 7 new positions and closed 8 in Q2 2024.
  • RTW Investments's portfolio value fell 4.7% quarter-over-quarter to $6.46B.

Based on RTW Investments's 13F filing for Q2 2024, filed 14 Aug 2024.